Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy

NCT ID: NCT06687876

Last Updated: 2025-07-10

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 14 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-03-09
• Study Completion Date: 2030-12-31

Brief Summary

The primary objective of this study is to investigate whether two weeks of metformin treatment can activate the tumour microenvironment in patients with stage II and III oesophageal adenocarcinomas.

Detailed Description

Worldwide oesophageal adenocarcinoma (OAC) is one of the most deadly cancers. Even in case of non-metastatic disease, when patients are treated with neoadjuvant chemoradiotherapy (nCRT) and a surgical resection, around 50% of patients suffer from recurrent disease which is associated with a poor prognosis. While 23% of OACs have a complete histopathological response after nCRT, 18-35% lack any effect of nCRT. Previously, we have identified that a complete pathological response to nCRT is associated with an active tumour immune microenvironment (TIME) characterized by high intratumoral T cell levels and a higher CD3:CD163 ratio.

To improve response to nCRT we need to identify and target the mechanisms OACs use to suppress the TIME. Using spatial transcriptomics to identify differences between OACs with a T cell-dominant and a T cell-excluded microenvironment, we identified fatty acid oxidation (FAO) as central feature of T cell low OACs (unpublished data). This is an interesting observation as lipid metabolism is strongly associated with an immunosuppressive microenvironment. Metabolic re-programming by drugs such as metformin has shown to be a promising strategy to reactivate the anti-tumour immune response in other cancer types.

Over the past decade, metformin has been associated with a beneficial effect in cancer treatment as it has shown to decrease the risk of various cancer types in diabetic patients. More recent, metformin treatment has shown to increase the number of CD8+ tumour infiltrating lymphocytes by preventing apoptosis of these lymphocytes in cancers such as oesophageal squamous cell carcinomas. In addition, metformin can reduce M2-like macrophage polarization due to changes in cytokine expression in cancer cells and thereby stimulate a more pro-inflammatory TIME. In this study we want to investigate the effect of metformin on the TIME in patients with OACs using pre- and post-treatment tumour biopsies prior to nCRT.

Conditions

Oesophageal Adenocarcinoma; Tumor Microenvironment

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Metformin

1000 mg (twice a day 500 mg) metformin orally will be administered during a 2-week period. This is followed by the standard of care, which is neoadjuvant chemoradiotherapy, involving paclitaxel (50 mg/m2), carboplatin (AUC=2), and radiotherapy (23 x 1.8 Gy over five weeks) followed by surgical resection.

Group Type: EXPERIMENTAL

Metformin

Intervention Type: DRUG

Twice a day 500mg of metfomrin orally (1000mg/day) during a 2-week period.

Interventions

Metformin

Twice a day 500mg of metfomrin orally (1000mg/day) during a 2-week period.

Intervention Type: DRUG

Other Intervention Names

Glucient

Eligibility Criteria

Inclusion Criteria

• Surgical resectable (<T4b, N0 or N+, M0), and histologically proven adenocarcinoma of the oesophagus or gastro-oesophageal junction planning to undergo neoadjuvant chemoradiotherapy.
• Adult patients (age ≥ 18 years).
• ECOG performance status 0 or 1 (cf. Appendix A).
• Adequate hematological, renal and hepatic functions defined as:

• Absolute Neutrophil Count ≥ 1.5 x 10^9/L
• Platelets ≥ 100 x 10^9/L
• Hemoglobin ≥ 5.6 mmol
• Total bilirubin ≤ 1.5 x upper normal limit
• Creatinine clearance (Cockroft) > 30 ml/min
• Patients must be willing to undergo two endoscopies for investigational purposes.
• Written, voluntary informed consent.
• Patients must be accessible to follow up and management in the treatment center.

Exclusion Criteria

• Patients diagnosed with diabetes mellitus type 1 or 2 receiving anti-diabetic drugs.
• Patients prescribed metformin or another anti-diabetic drug for any reason.
• Patients allergic or intolerant to metformin.
• Excessive alcohol consumption.
• Use of OCT1/OCT2 inhibitors (e.g. verapamil, cimetidine, dolutegravir, isavuonazol, trimethoprim, vandetanib, crizotinib and Olaparib).
• Use of OCT1/OCT2 inducers (e.g. rifampicine).
• Use of immunosuppressive medication (corticosteroids, cyclosporine, tacrolimus, sirolimus, everolimus, cyclophosphamide).
• Previous systemic therapy or radiotherapy on the oesophagus.
• Severe renal impairment (CLcr ≤ 30 ml/min).
• Past (within 5 years) or current history of malignancy other than entry diagnosis interfering with prognosis of oesophageal cancer.
• Previous systemic therapy for other forms of cancer within the last six months.
• Patients with prior allogeneic stem cell or solid organ transplantation
• Pregnancy (positive serum pregnancy test), planning to become pregnant, and lactation.
• Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) precluding major surgery.
• Pulmonary fibrosis, active, non-infectious pneumonitis and/or severely impaired lung function precluding major surgery and/or radiation.
• Serious underlying medical condition which would impair the ability of the patient to receive the planned treatment, including prior allergic reactions to drugs containing Cremophor, such as teniposide or cyclosporine.
• Dementia or altered mental status that would prohibit the understanding and giving of informed consent.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cancer Center Amsterdam Research Foundation

UNKNOWN

Sponsor Role: collaborator

Amsterdam UMC, location VUmc

OTHER

Sponsor Role: lead

Responsible Party

Sarah Derks

MD PhD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Sarah Derks, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Amsterdam UMC, location VUmc

Hanneke W.M. van Laarhoven, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Amsterdam UMC, location VUmc

Locations

Amsterdam UMC

Amsterdam, , Netherlands

Site Status: NOT_YET_RECRUITING

Amsterdam UMC

Amsterdam, , Netherlands

Site Status: RECRUITING

Countries

Netherlands

Central Contacts

Kayla Brugman, Master of Medicine

Role: CONTACT

c.brugman@amsterdamumc.nl

+3120 44 45869

Facility Contacts

Kayla Brugman

Role: primary

c.brugman@amsterdamumc.nl

+3120 44 45869

C.P. Brugman, MD

Role: primary

c.brugman@amsterdamumc.nl

02044445869

Other Identifiers

2024-511626-30-00

Identifier Type: CTIS

Identifier Source: secondary_id

2024.0935

Identifier Type: -

Identifier Source: org_study_id